

8:15	Registration and refreshments
9:00	Welcome and Network Information Prof Cal MacLennan, Director of BactiVac, UK Prof Adam Cunningham, Co-Director of BactiVac, UK
	Theme: Neglected Pathogens E-Coli Chair: Prof Alan McNally
9:15	The Evolution, Current Status, and Future Perspectives of ETEC and ExPEC Vaccine Development Dr Ibrahim Khalil, Department of Global Health, University of Washington, USA
9:45	Clinical development of a subunit ETEC vaccine Dr Chad Porter, Department Head, Translational and Clinical Research, Naval Medical Research Command, USA
10:15	Development vaccines against extra-intestinal Pathogenic E. coli (ExPEC) Dr Germie Van Den Dobbelen, Senior Director of Bacterial Vaccines & Immunology, The Janssen Pharmaceutical Companies of Johnson & Johnson, The Netherlands
10:45	Refreshments
	Theme: Neglected Pathogens Others Chair: Prof Richard Adegbola
11:15	Vaccines for Bacterial STIs: Challenges and Opportunities Dr Carolyn Deal, Branch Chief, Enteric and Sexually Transmitted Infections Branch, National Institute of Allergy and Infectious Diseases, USA
11:45	Development update of two late-stage Cholera & NTS vaccine candidates Dr Raches Ella, Chief Development Officer – Bharat Biotech, India
12:15	Lunch
	Theme: Manufacturing Chair: Prof Gordon Dougan
13:30	Manufacturing of bacterial vaccines from a DCVMN and Eubiologics perspective Dr Rachel Park, Director, EuBiologics Co., Ltd, South Korea
14:00	Enabling Vaccine Equitable Access Through Manufacturing Innovations Dr Ali Allouche, Vice President, Hilleman Labs, UK
14:30	Small Scale GMP manufacturing in Academia Dr Cath Green, Head of Clinical BioManufacturing, Nuffield Department of Medicine, University of Oxford, UK
15:00	Group Photograph Foyer, Edgbaston Park Hotel
15:10	Refreshments
15:30	Speed Networking Composers' Suite
17:00	Poster viewing and drinks reception Composers' Suite
18:30	Close of day programme
19:30	Conference Dinner Fry Suite

This programme is subject to change

	Theme: Failing Vaccines	Chair: Dr Ankur Mutreja
09:00	Pathogen evasion and escape from existing vaccines Prof Balaji Veeraraghavan, Professor in Clinical Bacteriology, Christian Medical College, India	
09:30	New aspects of an old disease: Diphtheria and toxigenic Corynebacterium spp. Prof Andreas Sing, Specialist in Microbiology and Infection Epidemiology, Bavarian State Office for Health and Food Safety (LGL), Germany	
	Theme: Working Together – Bridging the Gaps	Chair: Prof Janet Hemingway
10:00	The Power of Partnerships Dr Debbie King, Vaccine Research Lead, Infectious Disease Prevention, Wellcome, UK	
10:30	Considerations on veterinary bacterial vaccines Prof Peter Borriello, Trustee of Safe Medicines for Animals- regulatory training (SMart), UK	
11:00	Refreshments	
11:30	Oral Presentations from selected abstracts See Appendix 1	Chair: Dr Matt O'Shea
12:15	Lunch	
13:45	Oral Presentations from selected abstracts See Appendix 1	Chair: Dr Adrian Shields
14:30	Refreshments	
	Theme: Neglected Pathogens Group A Strep & Shigella	Chair: Dr Francesca Micoli
15:00	Group A Streptococcus vaccine pipeline Prof Andrew Steer, Director of Infection, Immunity and Global Health, Murdoch Children's Research Institute, Australia	
15:30	The road to a Strep A vaccine Dr Danilo Gomes Moriel, Senior Project Leader, GSK Vaccines Institute for Global Health	
16:00	Development of a Shigella multivalent bioconjugate vaccine: A phase I/II randomized, controlled and age descending study including dose finding in Kenyan infants Mr Chinaza Ezirim, Clinical Project Manager, LimmaTech Biologics AG, Switzerland	
16:30	Closing remarks for conference Prof Cal MacLennan, Director of BactiVac, UK Prof Adam Cunningham, Co-Director of BactiVac, UK	
16:45	Close of programme	

*Please do ensure that you complete the event evaluation form – this is most appreciated.
This programme is subject to change*

THURSDAY 19 October 2023

ABSTRACT ORAL PRESENTATIONS

	Oral Presentations from selected abstracts	Chair: Dr Matt O'Shea
11:30	Development of Large-Scale Antibody-Depleted Human Complement for Vaccine Immunogenicity Testing Dr Chris Lyle, Chief Technology Officer, Pel-Freez Biologicals, USA	
11:45	The protein target of a patient-derived fully-human monoclonal antibody against Neisseria meningitidis is a novel cross-protective antigen Dr Camilla Gladstone, Post-doctoral Research Associate, Imperial College London, UK	
12:00	Does maternal pertussis immunisation during pregnancy impact infant antibody responses to subsequent routine pertussis vaccines? Dr Anja Saso, Global Health Clinical PhD Fellow/Paediatrician, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, The Gambia	
12:15	Lunch	
	Oral Presentations from selected abstracts	Chair: Dr Adrian Shields
13:45	Development of bovine herpesvirus 4 (BoHV-4) as a safe, inexpensive, single-dose vaccine to control Streptococcus suis infection in domestic pigs Dr Hester Nichols, Project Lead, The Vaccine Group Ltd, UK	
14:00	Novel T-Cell-Based Vaccines to fight escape infections globally Miss Paulina Zarodkiewicz, PhD student, Queen's University Belfast, Northern Ireland	
14:15	Development and immunogenicity of carbohydrate-based vaccine against Group A Streptococcus Dr Sowmya Ajay Castro, Senior Research Associate, University of Dundee, UK	
14:30	Refreshments	

This programme is subject to change.